TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06479525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Toe Flexor Strengthening Exercises
Description: 16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calf Strengthening Exercises
Description: 16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
Study: NCT05849506

Intervention type: DEVICE
Intervention: Touch® Prosthesis
Description: The Touch® prosthesis is a medical device approved in Switzerland, which is an effective surgical treatment for advanced CMC I osteoarthritis.
Study: NCT04695821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senti V1.0 Device
Description: This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone.
Study: NCT05758272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile phone-based simple physical exercise reminder to help quit smoking
Description: Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular text-based intervention
Description: The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
Study: NCT05413122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
Study: NCT06260241

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traction Dressing
Description: Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.

Intervention type: OTHER
Group type: OTHER
Intervention: Without Traction Dressing
Description: Without Traction Dressing
Study: NCT05218746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
Study: NCT06201871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
Study: NCT05698329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: Periocular injection
Study: NCT05932706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High definition transcranial alternating current stimulation
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high definition transcranial alternating current stimulation
Description: In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
Study: NCT05528822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided pericapsular nerve group (PENG) block
Description: A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
Study: NCT05606198

Intervention type: OTHER
Intervention: Exposed to a SARS-CoV-2 infection
Description: The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Study: NCT04797598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality group
Description: This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic training group
Description: This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
Study: NCT04764201

Intervention type: DRUG
Group type: OTHER
Intervention: HIP2001
Description: Test drug

Intervention type: DRUG
Group type: OTHER
Intervention: HIP2001
Description: Test drug

Intervention type: DRUG
Group type: OTHER
Intervention: HGP2001
Description: Reference drug

Intervention type: DRUG
Group type: OTHER
Intervention: HGP2001
Description: Reference drug
Study: NCT05937815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
Study: NCT05413122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
Study: NCT06122454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepenofovir Fumarate Tablets
Description: Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepenofovir Fumarate Tablets
Description: Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
Study: NCT05431998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement
Description: the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the use of autogenous bone graft in the jumping gap during immediate implant placement
Description: the use of autogenous bone graft in the jumping gap during immediate implant placement
Study: NCT04732247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal treatment with oxytocin via nasal spray (48 IU per dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Intranasal treatment with placebo via nasal spray
Study: NCT06426095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A (instructional video),
Description: Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B (live demonstration)
Description: Participants in Group B were provided with live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group C (hybrid)
Description: Group C received a dual approach, combining instructional video guidance with live demonstrations.
Study: NCT03776162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction (Bone Patellar Tendon Bone Graft)
Description: Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Enhanced ACL Restoration (BEAR)
Description: The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
Study: NCT05376878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-Trastuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT05603897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)
Description: Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.

Intervention type: OTHER
Group type: OTHER
Intervention: Non-standardized clinical swallow evaluation
Description: Participants will receive current standard of care for dysphagia screening and treatment.
Study: NCT05425407

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey protein
Description: Daily 45g of whey protein supplementation during a three week eccentric training period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein + collagen peptide
Description: Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
Study: NCT05271318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILT-123
Description: Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILT-123
Description: Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab, a monoclonal antibody binding PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab, a monoclonal antibody binding PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
Study: NCT05722405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib plus low-dose lenalidomide
Description: Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone

Intervention type: DRUG
Group type: OTHER
Intervention: Ixazomib
Description: Ixazomib alone
Study: NCT05413122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
Study: NCT05187247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality glasses
Description: use of virtual reality glasses to reduce anxiety and pain levels
Study: NCT04173702

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: balance analysis
Description: Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
Study: NCT05821686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Interleukin-2 (IL-2) (Proleukin)
Description: All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
Study: NCT04151472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablet, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablet, three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90mg Idebenone
Description: Idebenone 30 MG Oral Tablet, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 270mg Idebenone
Description: Idebenone 90 MG Oral Tablet, three times a day
Study: NCT06011278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Supported Videos
Description: Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research.
Study: NCT06014502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGS-001
Description: Every 2 weeks
Study: NCT05639478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot-related exercises
Description: Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
Study: NCT05197114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: summerlunch+ At Home Food Skills Program
Description: The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
Study: NCT05154240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INS018_055
Description: INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05560750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frenotomy
Description: Releasing the tongue-tie with scissors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral physiotherapy
Description: Gentle parental activation of the mouth area and the tongue for 1 month
Study: NCT05139823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: geriatric follow-up home visit after discharge
Description: An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
Study: NCT04874623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of peripheral blood mononuclear cells
Description: Analysis of specific memory B cells in CDI patients